menu
    • menu

    Company profile for NewAmsterdam Pharma

    NEW Drugs in Dev: 1
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Founded in 2019, NewAmsterdam Pharma is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases. Its mission is to improve patient care in populations where traditional therapies have been unsuccessful or are not tolerated. In April 2020, NewAmsterdam acquired Dezima Pharma from Amgen, including all rights for obicetrapib (TA-8995), a novel, selective, choleste...
    Founded in 2019, NewAmsterdam Pharma is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases. Its mission is to improve patient care in populations where traditional therapies have been unsuccessful or are not tolerated. In April 2020, NewAmsterdam acquired Dezima Pharma from Amgen, including all rights for obicetrapib (TA-8995), a novel, selective, cholesteryl ester transfer protein (CETP) inhibitor. The Company is investigating obicetrapib as the preferred LDL-c lowering therapy for patients who cannot be treated optimally with current available lipid-lowering therapy.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    NewAmsterdam PharmaNetherlands1 Flag
    Country
    Country
    Netherlands
    Address
    Address
    Gooimeer 2-35 1411 DC Naarden The Netherlands
    Telephone
    Telephone
    +31 (0) 35 206 2971
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.newamsterdampharma.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    PBP World Meeting

    Not Confirmed

    envelop Contact Supplier

    PBP World Meeting

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    NewAmsterdam Pharma Grants Inducements Under Nasdaq Listing Rule
    NewAmsterdam Pharma Grants Inducements Under Nasdaq Listing Rule

    06 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/06/3251302/0/en/NewAmsterdam-Pharma-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    06 Mar 2026
    Share Share
    Newamsterdam Pharma Joins March Investor Conferences
    Newamsterdam Pharma Joins March Investor Conferences

    25 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/25/3244537/0/en/NewAmsterdam-Pharma-to-Participate-at-Upcoming-Investor-Conferences-in-March.html

    GLOBENEWSWIRE
    25 Feb 2026
    Share Share
    NewAmsterdam Pharma Unveils 2025 Financials And Corporate Update
    NewAmsterdam Pharma Unveils 2025 Financials And Corporate Update

    18 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/18/3240069/0/en/NewAmsterdam-Pharma-Reports-Full-Year-2025-Financial-Results-and-Provides-Corporate-Update.html

    GLOBENEWSWIRE
    18 Feb 2026
    Share Share
    Newamsterdam Pharma Discloses Inducement Grants Per Nasdaq Lr
    Newamsterdam Pharma Discloses Inducement Grants Per Nasdaq Lr

    06 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/06/3234067/0/en/NewAmsterdam-Pharma-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    06 Feb 2026
    Share Share
    Newamsterdam Pharma Presents At Guggenheim Biotech Summit 2026
    Newamsterdam Pharma Presents At Guggenheim Biotech Summit 2026

    04 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/04/3231963/0/en/NewAmsterdam-Pharma-to-Present-at-the-Guggenheim-Emerging-Outlook-Biotech-Summit.html

    GLOBENEWSWIRE
    04 Feb 2026
    Share Share
    Newamsterdam Pharma Showcases 2025 Successes, Sets 2026 Goals
    Newamsterdam Pharma Showcases 2025 Successes, Sets 2026 Goals

    09 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/09/3216046/0/en/NewAmsterdam-Pharma-Highlights-2025-Achievements-and-Outlines-2026-Strategic-Priorities.html

    GLOBENEWSWIRE
    09 Jan 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search